1. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). (28th November 2021) Authors: Mobarak, Sara; Salasi, Mehdi; Hormati, Ahmad; Khodadadi, Javad; Ziaee, Masood; Abedi, Farshid; Ebrahimzadeh, Azadeh; Azarkar, Zohreh; Mansour-Ghanaei, Fariborz; Joukar, Farahnaz; Yeganeh, Sara; Yaghubi Kalurazi, Tofigh; Naghipour, Mohammadreza; Mehrabi, Zeinab; Bahadori, Amir Reza; Yaghoubi, Shoe... Journal: Journal of antimicrobial chemotherapy Issue: Volume 77:Number 3(2022) Page Start: 758 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. (19th August 2020) Authors: Eslami, Gholamali; Mousaviasl, Sajedeh; Radmanesh, Esmat; Jelvay, Saeed; Bitaraf, Saeid; Simmons, Bryony; Wentzel, Hannah; Hill, Andrew; Sadeghi, Anahita; Freeman, James; Salmanzadeh, Shokrollah; Esmaeilian, Hani; Mobarak, Morteza; Tabibi, Ramin; Jafari Kashi, Amir Hosein; Lotfi, Zahra; Talebzade... Journal: Journal of antimicrobial chemotherapy Issue: Volume 75:Number 11(2020) Page Start: 3366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗